Nanog Antibody

Western Blot: Nanog Antibody [NB100-588]

Western Blot: Nanog Antibody [NB100-588] - The expression of pluripotency factor Nanog in human head and neck cancer cell lines cell lines FaDu and HN5. WB from a verified customer review.

Western Blot: Nanog Antibody [NB100-588]

Western Blot: Nanog Antibody [NB100-588] - Detection of mouse Nanog by western blot. Samples: Whole cell lysate (50 ug) from F9 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Nanog antibody NB100-588 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.

Western Blot: Nanog Antibody [NB100-588]

Western Blot: Nanog Antibody [NB100-588] - HIFs are required for hypoxia-induced expression of pluripotency factors. ZR75.1 cells were treated with vehicle or digoxin (200 nM), exposed to 20% or 1% O2 for 48 h, and HIF-1alpha, NANOG and SOX2 immunoblot assays were performed. Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/fulltext/11743), licensed under a CC-BY license.

Flow Cytometry: Nanog Antibody [NB100-588]

Flow Cytometry: Nanog Antibody [NB100-588] - staining of NTERA-2 cells using NB100-588 at a 1:50 dilution detected using Dylight-488 conjugated goat anti-rabbit secondary antibody.

Western Blot: Nanog Antibody [NB100-588] -

Western Blot: Nanog Antibody [NB100-588] - HIFs are required for hypoxia-induced expression of pluripotency factorsA-C. Breast cancer cell lines were exposed to 20% or 1% O2 for 24 h & NANOG (A), KLF4 (B), & SOX2 (C) mRNA levels were determined by RT-qPCR, relative to 18S rRNA, & normalized to the mean value for MDA-MB-231 cells (MDA231) at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. same cell line at 20% O2 by Student's t test. D & E. HCC-1954 (D) & MCF-7 (E) subclones, which were stably transfected with an expression vector encoding a non-targeting control (NTC) shRNA, or vector encoding shRNA targeting HIF-1 alpha (sh1 alpha) or HIF-2 alpha (sh2 alpha), or vectors encoding shRNAs targeting both HIF-1 alpha & HIF-2 alpha (DKD), were exposed to 20% or 1% O2 for 24 h & RT-qPCR was performed to determine NANOG (D) or KLF4 (E) mRNA levels relative to 18S rRNA. The results were normalized to NTC at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC at 20% O2; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. NTC at 1% O2 by ANOVA. F. ZR75.1 cells treated with vehicle or digoxin (200 nM) were exposed to 20% or 1% O2 for 24 h & SOX2 mRNA was measured (mean ± SEM; n = 3). *P < 0.05, **P < 0.01 vs. NTC at 20% O2; ###P < 0.001 vs. NTC at 1% O2 by ANOVA. G & H. NTC & DKD subclones of HCC-1954 (G) & MCF-7 (H) were exposed to 20% or 1% O2 for 48 h, whole cell lysates were prepared, & immunoblot assays were performed to analyze HIF-1 alpha, HIF-2 alpha, NANOG & KLF4 protein expression. Actin was also analyzed as a loading control. I. ZR75.1 cells were treated with vehicle or digoxin (200 nM), exposed to 20% or 1% O2 for 48 h, & HIF-1 alpha, NANOG & SOX2 immunoblot assays were performed. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.11743), licensed under a CC-BY license. Not internally tested by Novus Biologicals.